Back to results
US 2024/0180923 A1Published application
Methods of treating disorders with ulk inhibitors
AssigneeDeciphera Pharmaceuticals, LLC
InventorsRodrigo Ruiz Soto, Frederic J. Reu, Matthew L. Sherman, Daniel L. Flynn, Madhumita Bogdan, Bryan D. Smith, Gada Al-Ani
Life of this patent
Estimating the term…
Abstract
Described herein are compounds that are inhibitors of autophagy and their use in the treatment of disorders such as cancers.
Claims27
A method of treating cancer in a patient in need thereof, comprising:
- (i) administering to the patient about 20 mg to about 600 mg, once or twice daily, of a compound represented by Formula (I):
- or a pharmaceutically acceptable salt thereof;
- and
- (ii) administering to the patient a therapeutically effective amount of one or more additional therapeutic agents.
1 more element
6-10. (canceled)
13-34. (canceled)
A method of treating cancer in a patient in need thereof, comprising administering to the patient:
- (i) orally administering to the patient about 20 mg to about 600 mg, once or twice daily, of a compound represented by Formula (I):
- or a pharmaceutically acceptable salt thereof;
- and
- (ii) orally administering to the patient a therapeutically effective amount of a KRAS G12C inhibitor.
1 more element
42-62. (canceled)
A method of treating an advanced gastrointestinal stromal tumor in a patient in need thereof, comprising:
- (i) orally administering to the patient a therapeutically effective amount of a compound represented by Formula (I):
- or a pharmaceutically acceptable salt thereof;
- and
- (ii) orally administering to the patient a therapeutically effective amount of ripretinib.
1 more element
70-71. (canceled)
Dependencies are inferred from the claim text.